As the dust settles in the wake of the FOURIER trial results, how should we translate them into practice? Dr. Steven Nissen shares his thoughts on this, as well as PCSK9 inhibitor safety, in this two-minute video.
FOURIER was the big news out of ACC, but other PCSK9 inhibitor trials mattered as well, including its EBBINGHAUS substudy and the SPIRE and ORION-1 trials. Dr. Steven Nissen outlines the takeaways.
A major trial has finally shown that muscle-related statin intolerance is reproducible using a rechallenge procedure. Plus it offers insights on the tolerability and efficacy of alternatives in statin-intolerant patients.
Participating Cleveland Clinic investigator says evolocumab’s sustained LDL reductions over 11 months and halving of cardiovascular event rates suggest “we are on the right track” with PCSK9 inhibitors.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
PSCK9 inhibitors are demonstrating safe, significant LDL-lowering ability in patients for whom therapy with statins or ezetimibe is not sufficient or not tolerated.